ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Kalaris Therapeutics Inc (KLRS) stock declined over -8.30%, trading at $7.40 on NASDAQ, down from the previous close of $8.07. The stock opened at $7.63, fluctuating between $7.40 and $8.12 in the recent session.
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Employees | 14 |
Beta | 0 |
Sales or Revenue | N/A |
5Y Sales Change% | N/A |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |